Aubagio

(Teriflunomide)

Aubagio

Drug updated on 11/8/2023

Dosage FormTablet (oral; 7 mg, 14 mg)
Drug ClassPyrimidine synthesis inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • For the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Aubagio (teriflunomide) Prescribing Information.2022Genzyme Corporation, Cambridge, MA

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines